Foghorn Therapeutics has unveiled its strategic roadmap, emphasizing the advancement of its precision therapeutics pipeline, with a particular focus on oncology. The company is progressing ...

Jefferies lowered the firm’s price target on Foghorn Therapeutics (FHTX) to $14 from $18 and keeps a Buy rating on the shares after the company discontinued development of FHD-286 in acute ...

Foghorn Therapeutics on Monday said it is ending independent development of its FHD-286 drug candidate following disappointing results from an early-stage study. Foghorn said the objective ...

Foghorn Therapeutics (FHTX) has made the decision to discontinue the independent development of FHD-286 in combination with decitabine in patients with relapsed and/or refractory acute myeloid ...

Foghorn Therapeutics shares are trading lower by 20.2% during Monday's session. The company announced it will discontinue independent development of its FHD-286 program. Foghorn Therapeutics Inc ...

Foghorn Therapeutics has finally given up on its only wholly owned clinical-stage candidate after the troubled cancer drug came up short in a phase 1 study in patients with acute myeloid leukemia ...

Dec. 16, 2024 (GLOBE NEWSWIRE) -- Foghorn ® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines to treat serious diseases by correcting ...

CAMBRIDGE, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Foghorn ® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines to treat serious ...

A disused foghorn testing station in Dungeness is one of the unusual holiday lets on Kent's Romney Marsh. Renovated 15 years ago by the artist Fiona Naylor-Johnson, the building played a key role ...